Establishing the role of this site in vivo as well as potential functional interplay with previously identified GSK-3 sites has important implications for exploring GSK-3β as a therapeutic target to treat hyperlipidaemia of type-2 diabetes and obesity [64]. This evidence concerns the gene GSK3B and obesity due to melanocortin 4 receptor deficiency.